Quarterly ReportJul 1 – Sep 30, 2026
Sepsis, Q3 2026 edition
We read 2837 papers and selected 10.
Summary
Sepsis research in 2026-Q3 showed a clear transition from nonspecific syndrome management toward biologically defined, organ-specific, and phenotype-adapted strategies. Molecular diagnostics advanced from prospective paired-specimen ddPCR and direct-from-blood pathogen testing to a large randomized trial, while genomic epidemiology identified actionable reservoirs of neonatal antimicrobial-resistant transmission. Mechanistic research expanded knowledge of microbiota-derived metabolites, macrophage proteostasis and autophagy, renal metabolic injury, and septic cardiomyopathy. Prevention also gained importance through maternal group B Streptococcus vaccination and genomic infection-control approaches. Most therapeutic discoveries remained preclinical, but the quarter substantially strengthened the scientific basis for precision intervention and trial enrichment. Across studies, the need to connect biomarker or physiological improvement with patient-centered outcomes remained a consistent methodological lesson.
Selected Articles
1. Rapid and robust diagnosis of bloodstream infections by single-cell analysis.
The STREAM platform enriched pathogens directly from whole blood and combined single-cell identification with antimicrobial susceptibility testing. It achieved 96.15% concordance for pathogen identification, high susceptibility agreement across 219 drug-dose combinations, and complete results within 6.75–17 hours.
Impact: This study introduced an integrated diagnostic approach that combines rapid pathogen identification with susceptibility testing, directly addressing the time limitation of conventional culture.
Clinical Implications: STREAM could support earlier antimicrobial refinement, but prospective studies must determine its effects on effective therapy, antibiotic exposure, resistance, and mortality.
Key Findings
- Pathogen identification showed 96.15% concordance with clinical laboratory results.
- Complete diagnostic results were available within 6.75–17 hours.
- The platform simultaneously provided pathogen identification and antimicrobial susceptibility information.
2. Microbiota-derived isovalerate ameliorates sex-specific gut barrier dysfunction in malnutrition.
Using germ-free mice, targeted metabolomics, and human-derived colonoid monolayers, this study identified isovalerate as a regulator of intestinal barrier integrity. Isovalerate or leucine restored claudin-8 localization and reduced permeability in malnourished male mice, linking dysbiosis and bacterial translocation to sepsis risk.
Impact: The study connected microbiome metabolism, nutritional status, epithelial junction biology, and bacterial translocation using complementary experimental systems, advancing prevention-oriented sepsis biology.
Clinical Implications: Leucine supplementation or targeted isovalerate delivery may eventually be tested in malnourished patients, but human dosing, safety, microbiome dependence, and sex-specific effects require evaluation.
Key Findings
- Malnutrition increased intestinal permeability and bacterial translocation in male mice.
- Isovalerate improved epithelial barrier function in human-derived colonoid monolayers.
- Isovalerate or leucine restored claudin-8 localization and reduced permeability.
3. Arginase 2 deficiency mitigates sepsis-associated acute kidney injury by alleviating lipid accumulation.
Spatial metabolomics and proteomics identified increased ARG2 expression in renal tubular cells and macrophages during sepsis. Pharmacologic inhibition and renal tubule-specific knockdown reduced lipid accumulation, improved real-time glomerular filtration, and lowered blood urea nitrogen, with support from primary cells and human kidney organoids.
Impact: The study advanced sepsis-associated acute kidney injury from descriptive markers to a spatially defined and pharmacologically tractable metabolic mechanism.
Clinical Implications: ARG2 inhibition may become a kidney-protective strategy, but tissue selectivity, systemic arginine effects, host defense, therapeutic timing, and long-term safety require validation.
Key Findings
- ARG2 increased predominantly in renal tubular cells and macrophages.
- ARG2 inhibition or tubular knockdown reduced lipid accumulation and kidney injury.
- Protection was linked to restoration of PPARγ signaling and supported by human kidney organoids.
4. Plasma versus Whole Blood Multiplex Droplet Digital PCR for Pathogen Detection in ICU Patients with Clinically Suspected Sepsis: A Prospective Multicenter Cohort Study.
In 223 ICU patients, paired plasma and whole-blood multiplex ddPCR detected clinically relevant pathogens more frequently than blood culture alone in culture-negative suspected sepsis. Whole-blood ddPCR detected Candida more often than plasma ddPCR, supporting specimen-specific molecular testing.
Impact: This prospective multicenter study established clinically relevant evidence that specimen selection changes molecular pathogen yield, especially for suspected fungal sepsis.
Clinical Implications: Paired molecular testing may complement culture when rapid identification is needed, but it should not replace culture, clinical interpretation, or source-control assessment.
Key Findings
- Molecular testing identified clinically relevant pathogens in culture-negative suspected sepsis cases.
- Whole-blood ddPCR detected Candida more frequently than plasma ddPCR, 87.5% versus 31.3%.
- The study used prospective multicenter sampling and paired specimen comparison.
5. Transmission of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a Malawian neonatal unit: a clinical and genomic analysis of a prospective cohort study.
In a prospective mother-neonate cohort, whole-genome sequencing and transmission modeling linked invasive ESBL-producing Klebsiella isolates to stool and environmental reservoirs, especially sinks and oxygen-delivery equipment.
Impact: It translated genomic attribution into specific infection-control targets while addressing neonatal sepsis, antimicrobial resistance, and healthcare-associated transmission simultaneously.
Clinical Implications: Environmental decontamination, hand hygiene, stool containment, cot cleaning, and dedicated oxygen equipment should be prioritized for evaluation, but outcome-reducing effectiveness requires implementation studies.
Key Findings
- Forty-four of 90 evaluable neonates were colonized with ESBL-producing Klebsiella pneumoniae.
- Approximately 37%–65% of transmission was attributed to ward surfaces.
- Seventy-six percent of invasive isolates clustered genetically with stool or environmental isolates.
6. Diagnostic performance and antibiotic impact of droplet digital PCR in suspected sepsis: the PROGRESS trial.
The prospective multicenter randomized PROGRESS trial enrolled 1,373 patients with suspected sepsis. Pathogen-detection positivity was 54.1% with droplet digital PCR versus 21.6% with standard care, directly testing a molecular strategy intended to improve pathogen identification and antimicrobial refinement.
Impact: Its large randomized multicenter design provided the quarter's most clinically mature evidence for molecular pathogen detection in suspected sepsis.
Clinical Implications: ddPCR may support earlier antimicrobial refinement, but adoption requires data on turnaround time, antibiotic exposure, mortality, cost-effectiveness, and laboratory feasibility.
Key Findings
- The randomized multicenter trial enrolled 1,373 patients.
- Pathogen-detection positivity was 54.1% with ddPCR versus 21.6% with standard care.
- The intervention was designed to support pathogen-directed antibiotic adjustment.
7. Transglutaminase 2 regulates vimentin-dependent proteostasis during macrophage activation.
This study identified transglutaminase 2 as a driver of sepsis-associated liver inflammation and multiorgan injury. TG2 cross-linked vimentin in macrophages, promoting cytoskeletal remodeling and sustained inflammatory signaling, while genetic deletion or pharmacological inhibition improved survival in septic mice.
Impact: It revealed a previously underrecognized link between macrophage cytoskeletal proteostasis and systemic inflammation and supplied a druggable mechanism beyond broad immunosuppression.
Clinical Implications: TG2 inhibition is a candidate strategy for sepsis-associated liver dysfunction, but human target engagement, timing, dosing, and safety remain unresolved.
Key Findings
- TG2 activity increased in macrophages and promoted liver inflammation.
- TG2 cross-linked vimentin and sustained inflammatory signaling.
- Genetic or pharmacological TG2 inhibition improved survival and reduced multiorgan inflammation.
8. LAPTM5 Downregulation-Driven VAMP8 Phosphorylation Impairs Autophagosome-Lysosome Fusion and Aggravates Septic Acute Lung Injury.
Using patient samples, septic mouse models, macrophage-specific depletion, and viral rescue, this study identified LAPTM5 as a regulator of macrophage autophagic homeostasis. LAPTM5 promoted VAMP8 dephosphorylation, autophagosome-lysosome fusion, mitochondrial clearance, and reduced inflammatory lung injury.
Impact: It linked a patient-associated molecular abnormality to a cell-specific causal mechanism and defined an actionable pathway for septic lung injury.
Clinical Implications: LAPTM5-related autophagy may support future biomarker-guided therapy, but the evidence remains preclinical and does not justify changes to current management.
Key Findings
- LAPTM5 was downregulated in patient samples and septic mouse alveolar macrophages.
- Macrophage-specific Laptm5 depletion worsened, whereas overexpression improved, lung injury.
- LAPTM5 promoted autophagosome-lysosome fusion and mitochondrial clearance.
9. Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.
This randomized phase 1/2 trial evaluated a hexavalent group B Streptococcus conjugate vaccine in non-pregnant and pregnant participants and their infants. The program aims to prevent neonatal invasive GBS disease through maternal immunization and transplacental antibody transfer.
Impact: It extended sepsis research upstream from rescue treatment to population-level prevention of neonatal bloodstream infection, meningitis, and death.
Clinical Implications: The program supports phase 3 development, but pregnancy safety, gestational timing, antibody durability, serotype coverage, cost, and regional epidemiology require further study.
Key Findings
- A randomized phase 1/2 trial evaluated a hexavalent GBS conjugate vaccine.
- The program directly targets prevention of neonatal invasive GBS disease.
- Maternal immunization is intended to provide passive antibody protection to infants.
10. Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1-Driven Inflammatory Response.
This study identified a macrophage-specific PARP7-TBK1 regulatory axis that limits inflammation in septic cardiomyopathy. PARP7 deficiency worsened cardiac injury, whereas macrophage-targeted AAV9-mediated PARP7 expression was cardioprotective in two murine sepsis models.
Impact: It defined a cell-specific molecular brake on septic cardiac inflammation and validated targeted gene delivery in two experimental models.
Clinical Implications: PARP7 enhancement may become a strategy for septic cardiac dysfunction, but delivery specificity, immunogenicity, dosing, pathogen control, and safety require extensive validation.
Key Findings
- PARP7 deficiency exacerbated septic cardiomyopathy.
- PARP7 interacted with TBK1 through ADP-ribosylation and reduced TBK1-driven inflammation.
- Macrophage-targeted PARP7 expression improved experimental cardiac injury.